Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
3.030
+0.120 (4.12%)
At close: Aug 13, 2025, 4:00 PM
3.030
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:33 AM EDT
Taysha Gene Therapies Employees
Taysha Gene Therapies had 73 employees as of December 31, 2024. The number of employees increased by 21 or 40.38% compared to the previous year.
Employees
73
Change (1Y)
21
Growth (1Y)
40.38%
Revenue / Employee
$110,932
Profits / Employee
-$1,270,137
Market Cap
826.37M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 73 | 21 | 40.38% |
Dec 31, 2023 | 52 | -13 | -20.00% |
Dec 31, 2022 | 65 | -113 | -63.48% |
Dec 31, 2021 | 178 | 140 | 368.42% |
Dec 31, 2020 | 38 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TSHA News
- 1 day ago - Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 days ago - Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 - GlobeNewsWire
- 12 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program - GlobeNewsWire
- 2 months ago - Why Is Taysha Gene Therapies Stock Trading Higher On Thursday? - Benzinga
- 2 months ago - Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire